Condition
Aggressive B-cell Lymphomas
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Not Yet Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07514715Not Yet RecruitingPrimary
Proof of Concept for Real-time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B-Cell Lymphomas
NCT02205333Phase 1Terminated
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Showing all 2 trials